ACR 2026 – Day 1 Report
ACR Convergence was off to a big start with the year in review, posters and plenary sessions. Here are a few of my favorite presentations from todays Plenary I session at ACR Convergence.
Search for Terms or Answers
ACR Convergence was off to a big start with the year in review, posters and plenary sessions. Here are a few of my favorite presentations from todays Plenary I session at ACR Convergence.
Consider holding methotrexate for two weeks after each recombinant zoster vaccine dose when disease is stable, and give the vaccine before rituximab when timing allows.
While there is plenty to watch this ACR in the maturing CAR-T space, one of the big global stories in the second half of 2026 has been about zola-cel and the pause in the Breakfree program.
Innate immune dysregulation drives premature atherosclerosis in SLE, and it explains much of the cardiovascular risk that Framingham factors and medications do not. The main driver is a self-amplifying loop between type I interferon (IFN) and neutrophil extracellular traps (NETs).
Eosinophilic granulomatosis with polyangiitis (EGPA) is the rarest of the ANCA-associated vasculitides. Compared to GPA and MPA, EGPA carries a mechanistically unique pathophysiology involving eosinophil-mediated inflammation.
Every rheumatologist knows this patient. Her ASDAS is 3.4. Her CRP is normal, her MRI is quiet, and she is on her third biologic. The reflex is to reach for a fourth. Abstracts from ACR Convergence 2026 make a quietly radical case against this reflex.
New research presented at ACR Convergence 2026 examines pediatric patient’s symptoms and potential therapies that can assist children and adolescents with symptom control, as research, medication and therapies are currently limited.
ACR Convergence 2026 runs November 6–11 in Orlando, and the major companies will be presenting their highlight trials this week. Phase 3 results in Sjögren's and gout headline the late-breaking orals, while plenaries feature a head-to-head PsA trial and lupus nephritis biopsy data.
ACR Convergence 2026 is crowded with first-in-class mechanisms: an oral IL-23 receptor peptide, FcRn blockade, a JAK head-to-head and a wave of cell depletion therapies. Top abstracts include (all times ET):
Argenx
Dr. Jack Cush reviews the FDA approvals and news reports from this past week on RheumNow.com. This week we discuss playing the numbers in rheumatology, playing the long game with stem cell transplants, and a=the Positive spin on seronegative RA.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.